eli lilly and company

Eli Lilly cuts price of weight-loss drug Zepbound

Eli Lilly Introduces New Weight Loss Drug Doses, Lowers Price Points

Eli Lilly & Co. said Tuesday that it has launched new doses of its obesity treatment drug and reduced its prices. The pharmaceutical company said it has launched 7.5 and 10 milligram single dose vials of its Zepbound drug,

MarketWatch · 32m

Eli Lilly to Offer Higher Doses of Obesity Drug Zepbound at Discounted Prices

Eli Lilly is expanding its offerings of its hit weight-loss drug Zepbound for people who want to pay cash instead of using their health plans, and reducing prices for certain dosages. The pharmaceutical company said it would start selling higher dosages of its Zepbound drug,

YAHOO!Finance · 3h

Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients

Eli Lilly and Company (NYSE: LLY) announced the launch of 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, available for $499 with the new Zepbound Self Pay Journey Program.1 Lilly also reduced the price of the 2.

STAT · 3h

Eli Lilly to lower price of Zepbound vials, offer more doses

Eli Lilly said Tuesday that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells.

Investing · 3h

Eli Lilly launches new Zepbound vials, reduces prices under Self Pay Journey Program

Joe Nadglowski, president and CEO of the Obesity Action (WA: ACT) Coalition (OAC), appreciated Lilly's efforts to make obesity treatment more affordable. He emphasized, however, the need for continued progress in creating a health care system offering comprehensive care, coverage, and payment for individuals with obesity, free of weight bias.

Finanznachrichten · 1h

Eli Lilly and Company: Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients

New 7.5 mg and 10 mg Zepbound single-dose vials now available for $499 per month via Zepbound Self Pay Journey Program 2.5 mg and 5 mg vial prices reduced INDIANAPOLIS

MarketWatch · 4h

Eli Lilly cuts price of weight-loss drug Zepbound for self-paying patients

The drug company is calling on insurers and federal programs to include coverage of obesity as a chronic disease.

CNBC on MSN · 3h

Eli Lilly is selling higher-dose vials of Zepbound at a lower price to boost weight loss drug access

Eli Lilly is offering higher-dose vials through its direct-to-consumer website, LillyDirect, which started offering lower doses in vials in August.

11mon MSN

Hims & Hers Stumbles as GLP-1 Compounding Ends. Lilly Presses the Advantage.

Eli Lilly releases cheaper vials of the weight-loss drug for self-paying patients and cuts the price of two existing doses.

Eli Lilly: Load Up Before It Leaves You Behind

Eli Lilly stock surges past $840, outperforming the S&P 500. Click here to learn why LLY stock is still undervalued and why ...

Yahoo Finance3d

Eli Lilly and Company (LLY)

Eli Lilly and Company (NYSE: LLY) will participate in TD Cowen's 45th Annual Health Care Conference on March 4, 2025. Jake Van Naarden, executive vice president and president, Lilly Oncology ...

5don MSN

Eli Lilly aims to invest in ‘big problems hiding in plain sight' using obesity windfall

Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...

Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company

Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel ...